Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes.
Artigo
em Inglês
| IMSEAR
| ID: sea-45282
ABSTRACT
OBJECTIVE:
To compare the efficacy and safety profile of brimonidine as adjunctive therapy to beta-blockers between primary open angle glaucoma (POAG) and chronic angle closure glaucoma (CACG) in Asian eyes.DESIGN:
Three-months, open-label, prospective study.PARTICIPANTS:
Twenty-three patients (35 eyes) with POAG and 25 patients (39 eyes) with CACG were enrolled in the study. INTERVENTION Patients with POAG or CACG post iridectomy whose IOP was inadequately controlled with topical beta-blocker monotherapy were included. Then, brimonidine 0.2 per cent was added twice daily in both groups. Study visit occurred at weeks 2, 4, 8, and 12. Complete ophthalmic examinations were performed in all visits. MAIN OUTCOMEMEASURES:
Efficacy was determined by reduction in IOP from baseline and tolerability was assessed by reports of adverse events.RESULTS:
After 3 months of brimonidine adjunctive treatment, the mean (+/- SEM) IOP reduction were 4.37+/-0.34 mmHg (19.4%) in POAG and 4.54+/-0.37 mmHg (20.1%) in CACG (p= 0.741). No serious ocular or systemic adverse event was reported.CONCLUSION:
Brimonidine was well tolerated, efficacious and provided additive IOP reduction in POAG and CACG.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Quinoxalinas
/
Tailândia
/
Feminino
/
Humanos
/
Masculino
/
Glaucoma de Ângulo Fechado
/
Glaucoma de Ângulo Aberto
/
Estudos Prospectivos
/
Resultado do Tratamento
/
Agonistas alfa-Adrenérgicos
Tipo de estudo:
Estudo observacional
País/Região como assunto:
Ásia
Idioma:
Inglês
Ano de publicação:
2002
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS